The abstract is read at the publisher; the summary is JClub's.
In first-line metastatic pancreatic ductal adenocarcinoma, intravenous VCN-01 plus gemcitabine/nab-paclitaxel improved overall survival versus GnP alone in the full analysis set (10.8 vs 8.6 months; HR 0.57).
- Why it matters: Outcomes remain poor for metastatic pancreatic ductal adenocarcinoma, and prior evidence for VCN-01 needed confirmation in a randomized setting with standard chemotherapy.
- What they did: In a randomized phase 2b trial, patients received two VCN-01 doses with gemcitabine/nab-paclitaxel or GnP alone; primary endpoints were overall survival and safety, with efficacy also assessed by PFS and response measures.
- The result: Overall survival met the primary efficacy endpoint in the full analysis set, with longer duration of response (11.2 vs 5.4 months; HR 0.22) and higher 15- and 18-month survival rates; VCN-01 increased viral-related events, with serious events in 22.6% of patients.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.